Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend]
SEC Accession No. 0001193805-26-000493
Filing Date
2026-04-22
Accepted
2026-04-22 16:56:18
Documents
13
Period of Report
2025-12-31

Document Format Files

Seq Description Document Type Size
1 e665391_10ka-immunic.htm   iXBRL 10-K/A 481702
2 e665391_ex31-1.htm EX-31.1 3484
3 e665391_ex31-2.htm EX-31.2 3645
  Complete submission text file 0001193805-26-000493.txt   752822

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE imux-20251231.xsd EX-101.SCH 3002
5 XBRL LABEL FILE imux-20251231_lab.xml EX-101.LAB 34866
6 XBRL PRESENTATION FILE imux-20251231_pre.xml EX-101.PRE 22750
16 EXTRACTED XBRL INSTANCE DOCUMENT e665391_10ka-immunic_htm.xml XML 6754
Mailing Address 1200 AVENUE OF THE AMERICAS SUITE 200 NEW YORK X1 10036
Business Address 1200 AVENUE OF THE AMERICAS SUITE 200 NEW YORK X1 10036 (332) 255-9818
IMMUNIC, INC. (Filer) CIK: 0001280776 (see all company filings)

EIN.: 562358443 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-K/A | Act: 34 | File No.: 001-36201 | Film No.: 26884513
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)